TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03166787

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Charcoal hookah
Description: The Myocardial Blood Flow (MBF) will be measured at rest and during the last minute of a 3-minute bout of handgrip at 30% Maximal voluntary contraction. This sequence will be performed before and after 12 young hookah smokers are randomized to smoke the same popular Starbuzz tobacco product heated with either charcoal for 30 min each.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-coal hookah
Description: The Myocardial Blood Flow (MBF) will be measured at rest and during the last minute of a 3-minute bout of handgrip at 30% Maximal voluntary contraction. This sequence will be performed before and after 12 young hookah smokers are randomized to smoke the same popular Starbuzz tobacco product heated with electrically (Global First e-coal, ) for 30 min each.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarette
Description: The Myocardial Blood Flow (MBF) will be measured at rest and during the last minute of a 3-minute bout of handgrip at 30% Maximal voluntary contraction. This sequence will be performed before and after 12 young cigarette smokers smoke 2 cigarettes down to the stub over 30 min (to simulate real-world use).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbon Monoxide inhalation
Description: A subset (n=8) of the young hookah smokers will return on a later day and will be randomized to have coronary endothelial function assessed before and after inhaling 0.3 CO gas from a Douglas bag.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Room Air inhalation
Description: A subset 8 of the young hookah smokers will return on a later day and will be randomized to have coronary endothelial function assessed before and after inhaling room air from a Douglas bag.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin C
Description: in a subset of 6 subjects the study team will repeat the Myocardial Contrast Echocardiography and speckle tracking studies after pretreatment with either i.v. vitamin C .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tadalafil
Description: in a subset of 6 subjects the study team will repeat the Myocardial Contrast Echocardiography and speckle tracking studies after pretreatment with one dose of oral tadalafil.
Study: NCT03026946

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alitretinoin
Description: Oral alitretinoin capsule of 30mg once daily for a total of 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporin A
Description: Oral cyclosporine A start dose 5 mg/kg/day (split in 2 doses), decreasing the dose after 8 weeks to 3 - 3.5 mg/kg/day (split in 2 doses). The treatment period is 24 weeks.
Study: NCT05007119

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mckenzie Extension Protocol
Description: Moist Heat Pack for 10 mins McKenzie Extension Protocol Sequence~Static:~1. Lying Prone~2. Lying prone in extension~3. Sustained extension~4. Posture correction~   Dynamic:~5. Extension in lying~6. Extension in lying with clinician overpressure~7. Extension mobilization~8. Extension in standing

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mckenzie Extension Protocol
Description: Moist Heat Pack for 10 mins McKenzie Extension Protocol Sequence~Static:~1. Lying Prone~2. Lying prone in extension~3. Sustained extension~4. Posture correction~   Dynamic:~5. Extension in lying~6. Extension in lying with clinician overpressure~7. Extension mobilization~8. Extension in standing

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cupping
Description: Cupping with blood letting
Study: NCT00467519

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tdap (Tetanus Toxoid Reduced Diphtheria Toxoid/Acellular Pertussis)
Description: 0.5 mL, IM
Study: NCT03796377

Intervention type: DRUG
Group type: OTHER
Intervention: St Johns Wort Extract
Description: 20 mg rivaroxaban after supplementation with St. John's wort extract (Jarsin®) twice daily 450 mg po for 2 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Rivaroxaban
Description: 20 mg rivaroxaban.

Intervention type: DRUG
Group type: OTHER
Intervention: Rivaroxaban
Description: 20 mg rivaroxaban.
Study: NCT02512731

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Esophageal Doppler Monitor
Description: Esophageal doppler monitoring (EDM) is a minimally invasive means of continuously measuring the cardiac output from the pattern of blood flow in the descending thoracic aorta.
Study: NCT00704899

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Structured exercise regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitryptiline
Description: Amitryptiline 25mg once daily
Study: NCT00467519

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP (Diphtheria & Tetanus Toxoids & Acellular Pertussis Adsorbed)
Description: 0.5 mL, IM
Study: NCT01367015

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Feeding
Description: Feeding with expressed breast milk @ 8ml/kg/day for 48 hrs after randomization at 60+/-12 hrs of life

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Late Feeding
Description: Nil per oral for another 48 hrs after randomization at 60+/-12 hrs of life followed by Feeding with expressed breast milk @ 8ml/kg/day for 48 hrs
Study: NCT01516138

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GIK
Description: Intravenous solution was started at about 10 minutes before general anesthesia, running at a rate of 1 mL/kg/h for 12.5 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Intravenous solution was started at about 10 minutes before general anesthesia, running at a rate of 1 mL/kg/h for 12.5 hours.
Study: NCT02823353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: Fenofibrate 200mg/day
Study: NCT02767336

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Glucose Monitoring System.
Description: In vitro diagnostic medical device
Study: NCT02823353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UDCA
Description: UDCA 13-15mg/kg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UDCA
Description: UDCA 13-15mg/kg/day
Study: NCT02657044

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EMR

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESD
Study: NCT05355285

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glucose Clamp
Description: Subjects receive variable rates of glucose or insulin infusions to adjust and maintain desired plasma glucose or insulin levels.
Study: NCT00316017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7.5% hypertonic saline/6% Dextran-70 (HSD)
Description: 250 cc dose given as a one-time intravenous (IV) bolus in the pre-hospital setting.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7.5% hypertonic saline (HS)
Description: 250 cc dose given as a one-time IV bolus in the pre-hospital setting.
Study: NCT05355285

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glucose Clamp
Description: Subjects receive variable rates of glucose or insulin infusions to adjust and maintain desired plasma glucose or insulin levels.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glucose Clamp
Description: Subjects receive variable rates of glucose or insulin infusions to adjust and maintain desired plasma glucose or insulin levels.
Study: NCT02115100

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: procedure
Description: Renal ablation+pulmonary vein isolation OR pulmonary vein isolation only

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: procedure
Description: Renal ablation+pulmonary vein isolation OR pulmonary vein isolation only
Study: NCT03973580

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attentional Bias Modification (ABM) task
Description: Participants will be presented with a fixation cross (500ms) followed by a pair of identity-matched, angry-neutral faces (1000ms). The pair presentation is replaced by a single arrow-probe (1000ms) in the position of the neural face. Inter-trial intervals (ITI) are 500ms. Participants indicate arrow direction (left or right) by pressing one of two buttons as quickly as possible. By responding to the probe that always replaces the neutral face, participants learn to attend to the non-threat cues and away from threat cues. There are 120 trials of angry-neutral faces in total, and 40 other catch trials with neutral-neutral faces.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control task
Description: The control task is identical with the ABM task, except that in the 120 angry-neutral trials, the arrow-probe replaces the angry face and the neutral face with equal probabilities (60 trials each).
Study: NCT01483638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axitinib
Description: 5 mg BID taken orally with food continuously on Day 1 of the study. One cycle corresponds to 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: will be administered orally with the same schedule of axitinib
Study: NCT04327921

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer navigation social support for smoking cessation
Description: Standard guidelines will be used for brief advice for smoking cessation based on the 5A's. Also, motivational interviewing/guidance will also be used to determine whether enhanced treatment (using a Peer Navigator to navigate smoking cessation, obtain medication and treatment, improve adherence to treatment, and provide social support for quitting) will increase participant's quit attempts and smoking cessation rates.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Condition
Description: Standard guidelines will be used for brief advice for smoking cessation based on the 5A's.
Study: NCT01394289

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lolium allergen extract
Description: This is an open, unblinded and non randomized biological as proposed by the Nordic Guidelines.~Four concentrations of Lolium perenne allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test.
Study: NCT02552108

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural experiments for intolerance of uncertainty (BE-IU)
Study: NCT04500444

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise training
Description: An aerobic exercise program with blood flow restriction will be applied 4 times a week for a total of 6 weeks. The aerobic exercise training consists of a warm up period for 5 minutes, walking on treadmill at 4 km per hour speed for 20 minutes and cooling down for another 5 minutes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: exercise training
Description: An aerobic exercise program with blood flow restriction will be applied 4 times a week for a total of 6 weeks. The aerobic exercise training consists of a warm up period for 5 minutes, walking on treadmill at 4 km per hour speed for 20 minutes and cooling down for another 5 minutes.
Study: NCT04622566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib, Pembrolizumab
Description: After enrollment, patients receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for 6 weeks; Lenvatinib 20mg orally once daily for 6 weeks. Patients conduct surgery within 1-4 weeks after the last dose of Pembrolizumab and Lenvatinib. After complete surgery, Pembrolizumab will be as adjuvant treatment for up to 15 cycles, 200mg IV on day 1 of every 21 day-cycles.
Study: NCT01705938

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SP-333

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SP-333

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SP-333

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SP-333

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SP-333

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SP-333

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SP-333
Study: NCT03830268

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: No MCT intake with breakfast, no lunch
Description: Water given with a regular standardize breakfast and water given at noon without lunch.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: No MCT intake with lunch, no breakfast
Description: Water given in the beginning of the metabolic study day without breakfast and water given at noon with a regular standardize lunch.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10g of Betaquik
Description: BQ10 given with a regular standardize breakfast and BQ10 given at noon without lunch.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10g of Betaquik
Description: BQ10 given with a regular standardize breakfast and BQ10 given at noon without lunch.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10g of Betaquik with low-carbs breakfast
Description: BQ10 given with a low-carbs standardize breakfast and BQ10 given at noon without lunch.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 20g of Betaquik
Description: BQ20 given with a regular standardize breakfast and BQ20 given at noon without lunch.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10g of Betaquik with lunch, no breakfast
Description: BQ10 given in the beginning of the metabolic study day without breakfast and BQ10 given at noon with a regular standardize lunch.
Study: NCT02198846

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: insulin pump
Description: stop any antihyperglycemic medication and convert to insulin pump
Study: NCT00316017

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% normal saline
Description: 250 cc dose given as a one-time IV bolus in the pre-hospital setting.
Study: NCT02198846

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment
Description: intensification of conventional treatment by adding oral antihyperglycemic agents or subcutaneous insulin (once / twice/ multiple injection)
Study: NCT02144870

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Habit Reversal Training
Description: awareness training, competing response training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resources activation
Study: NCT02523430

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: interventional therapy
Description: nasopharyngeal carcinoma patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: interventional therapy
Description: nasopharyngeal carcinoma patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
Study: NCT02557399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duac® fixed dose combination gel
Description: Duac® fixed dose combination gel containing clindamycin phosphate 1.2% and benzoyl peroxide 3%.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADA 0.1% gel
Description: ADA 0.1% gel containing 0.1% of adapalene.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CLDM 1% gel
Description: CLDM 1% gel containing clindamycin phosphate 1.2% (1% as clindamycin).
Study: NCT00924846

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High frequency oscillatory ventilation
Description: Mechanical ventilation as high frequency oscillatory ventilation for 8h periods

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High frequency oscillatory ventilation
Description: Mechanical ventilation as high frequency oscillatory ventilation for 8h periods
Study: NCT00596271

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IC51

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IC51

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HAVRIX

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HAVRIX

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT00577317

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Management of Therapy Complications
Description: Receive standard home maintenance therapy and perform self-manual lymphatic drainage
Study: NCT00565487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine, Tarceva
Description: Capecitabine is a self-administered (oral) medication \& will be dose escalated and administered in four dose levels: Level I - 600 mg/m2 bid; Level II - 700 mg/m2 bid; Level III - 825 mg/m2 bid; Level IV - 925 mg/m2 bid. Tarceva will be self-administered(orally) in an open-label, unblinded manner to all patients enrolled in the study. During the treatment period, patients will receive single agent Tarceva 100 mg/day. Treatment of Capecitabine \& Tarceva is continued daily until the completeness of the radiation or toxicity.
Study: NCT04157400

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoperative Parameter Testing
Description: Step 1: Recording and stimulation of spinal potentials during insertion of epidural spinal stimulator paddle~Once the epidural paddle is placed, study procedures will begin by connecting the terminals of the paddle to an electrophysiological recording device for signal amplification and filtering. Using this recording setup, motor evoked potential (MEP) and somatosensory evoked potential (SSEP) protocols will be performed to determine motor and sensory thresholds, respectively. Next, the surgical procedure will resume and after the implantable pulse generator (IPG) has been placed, study procedures will begin again and include activation of both low-frequency tonic stimulation (LFTS) and high-frequency burst stimulation (HFBS) patterns from the inserted paddle while recording EMG signals.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proprioception Testing During Stimulation
Description: Step 3: Proprioception testing~The research team will investigate the perceived change in knee joint angle and direction of movement reported by the subject in a Threshold to Detect Passive Movement (TTDPM). The TTDPM protocol will begin with the subject sitting in the Biodex testing seat, with the non-tested leg hanging freely and the tested leg strapped to the rotating arm of the dynamometer at the lower shank. The subject will be blinded as to the mode and intensity of stimulation: HFBS, LFTS, or no stim. The TTDPM will consist of at least 10 trials for each stimulation condition chosen based on SCM outcomes. The subject has control of a kill-switch that immediately halts movement of the rotating arm, which is to be activated once the subject perceives movement OR if the subject begins to feel any pain or discomfort throughout the task.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gait Analysis During Stimulation
Description: Step 4: Body weight support and treadmill (BWST) testing~Similar to step 2, LFTS and HFBS patterns will be compared by systematically testing each individual contact on the paddle while investigating for changes in stepping speed, pattern and EMG moduling complexity. Regarding EMG module analysis, muscle activity will be recorded bilaterally via surface EMG from lower extremity musculature. Furthermore, subjects will also have active LED markers placed over their clothes in order to track whole body kinematics throughout this portion of the study.~To optimize capture of steady state data on the treadmill, each subject will walk for approximately 10 sec prior to the 30 sec of data collection (40 sec per trial). This will allow capture of at least 10 consecutive steady state gait cycles (depending on cadence) per each amplitude selection for each stimulation delivery technique, which will be defined by parameters found during walking SCM.
Study: NCT00045773

Intervention type: DRUG
Intervention: Sertraline
Description: 50 - 200mg, once per day for 12 weeks.
Study: NCT03953755

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tricuspid valve repair
Description: Tricuspid valve repair
Study: NCT01585155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-650
Description: TA-650 will be intravenously infused at 5 mg/kg as an induction regimen at Weeks 0, 2, 6. For subjects who meet the responder criteria, TA-650 will be administered at 8-week intervals thereafter until week 22.
Study: NCT00659555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib eye drops
Description: Pazopanib will be administered as eye drop solution via topical ocular route. Pazopanib eye drops will be available as white, colorless solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib eye drops
Description: Pazopanib will be administered as eye drop solution via topical ocular route. Pazopanib eye drops will be available as white, colorless solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconozole tablets
Description: Ketoconozole will be administered as tablets via oral route. Ketoconozole tablets will be present as white, rounded, scored tablets
Study: NCT00577317

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Management of Therapy Complications
Description: Receive Flexitouch home maintenance therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT03045939

Intervention type: DEVICE
Group type: OTHER
Intervention: cervical ripening device
Description: insertion of the double balloon device for 12 hours (standard care) vs 6 hours, following oxytocin IV infusion according local protocol guidelines as mentioned above

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cervical ripening device
Description: insertion of the double balloon device for 12 hours (standard care) vs 6 hours, following oxytocin IV infusion according local protocol guidelines as mentioned above
Study: NCT00925353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4% lidocaine gel
Description: 1 ounce 4% lidocaine gel on skin of breasts and chest wall for 1 hour under occlusion, then removed with warm water
Study: NCT02729064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humulin R
Description: Study subjects will receive intranasal insulin (Humulin R) via a metered nasal dispenser.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humulin R
Description: Study subjects will receive intranasal insulin (Humulin R) via a metered nasal dispenser.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Study subjects will receive intranasal placebo (normal saline) via a metered nasal dispenser.